Popular on Rezul
- Amid Controversy with The Weeknd/Playboi Carti and Buzz Surrounding His Upcoming Project, Darrin Jones Drops Soulful New Single "Under Control"
- For Saving Home Services Inc: Easy-Approval HVAC Financing in Toronto for Affordable Furnace
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- Rainbow Property Maintenance Launches Cost-Effective, High-Quality Medical Cleaning Services
- Steve Nosrat Joins The Mogharebi Group to Lead Las Vegas Office
- First-Time Homebuyers Face Challenges as Starter Homes Disappear in 2025
- Titan Pressure Washing Selected a 2024 Nextdoor Neighborhood Faves for Best Pressure Washing Service
- ®Grammy Award Winner Alex Cuba releases new single "El Día Más Triste"
- LAIIER Closes Oversubscribed US$4M Seed Extension Funding Round, Led by Closed Loop Partners
- Country Creek Condominium Chooses Corner Property to Manage its Picturesque Residential Community
Similar on Rezul
- Explore the "Magic of Rainbows" in the New Children's Book Series "Mila and Ally's STEMventures
- Relentless 2800 Challenge: A 40-Day Team Fitness Journey Launching for Lent 2025
- Maryland Bill Aims to Curb Mental Health Youth Transport Abuses
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
- Volante of Hanover Expands with the Opening of Its Second Building, Introduces Assisted Living Services
- New Jersey Sober Living Opens New Luxury Themed Facility in South New Jersey
- Hawaii Bill Marks Progress in Protecting Patients From Dangerous Restraint Practices
- Gold Coast Health Plan Distributes $225,000 for Fire Relief and Preparedness Efforts
- Gold Coast Health Plan Among State's Top Performers for Outstanding Health Care Quality
Neurolixis expands rare autism disorders research program
Rezul News/10670167
Neurolixis issued a new US patent for treatment of Fragile X syndrome with NLX-101
PARK RIDGE, N.J. - Rezul -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that the United States Patent and Trademark Office (USPTO) granted a patent (US11974992B2) covering the use of NLX-101, a clinical phase drug candidate, for treatment of Fragile X syndrome (FXS). FXS is a rare genetic autism spectrum disorder which affects about 1 in 5000 individuals and is a leading cause of inherited intellectual disability. There are no approved treatments for Fragile X syndrome.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on Rezul News
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on Rezul News
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on Rezul News
- New Estate Agency Set To Shake Up Gosforth Property Market
- Winter Weather Woes? Triple Diamond Construction Offers Free Roof Assessments for OKC Homeowners
- Lennar opens a new model home at TrailMark
- Unlock the Hidden Power of Dreams in The Lucid War Chronicles
- AAGLA Signs With CredHub to Help Owners Comply with New Rent Reporting Requirements
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on Rezul News
- Hardwood or Tile? A Homeowner's Guide to Choosing the Right Flooring
- Explore the "Magic of Rainbows" in the New Children's Book Series "Mila and Ally's STEMventures
- Integrity Storage Group Appoints Greg Head as Chairman of the Board
- Victoria Crossing Welcomes Corner Property Management as New Partner in Community Excellence
- Relentless 2800 Challenge: A 40-Day Team Fitness Journey Launching for Lent 2025
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
Source: Neurolixis, Inc.
0 Comments
Latest on Rezul News
- Popular Senior Housing Series Continues
- RNGD Opens New Headquarters Campus, Connecting Construction Operations, Manufacturing Operations and Training Center
- Cura HR's CEO, Lyssa Hansard, Featured in Forbes: Driving Meaningful Change in Pay Equity
- Zezgo Rent A Car has arrived In Cyprus to Improve Car Rental Options
- Meredith Thomas Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Kim Estes Returns as Master of Ceremonies for International Women's Day Gala for 2025
- Fire and Rescue Statistics Highlight Ongoing Fire Risks in UK Homes
- Andre Kay Honored with Black Excellence Award by the Florida Panthers
- Wide range of dental care products at upto 40% discounted prices | DentistryDeal.com
- NaturismRE, ANF, and GNA Stand United for Naturist Rights in Australia – A Call for Global Support
- RE/MAX Evergreen Welcomes New Brokers Joaquin and Rebecca Robideau
- Volante of Hanover Expands with the Opening of Its Second Building, Introduces Assisted Living Services
- Summerwoods Parrish Florida - Community Open House on Sunday, February 16th from 12-2 PM
- Talent Concierge® Artists Agency and The Big Talk® Announce Game-Changing Partnership Challenging Status Quo in the Meetings Industry
- FlyBright Pilot Academy Partners with Allegiant Air to Address the Pilot Shortage
- Spacious 5-Bedroom Home on 3 Acres in Locust Grove, GA – Open House This Sunday
- BEPeterson Building Engineering Partnerships
- WonderDays: The Startup Disrupting the UK Gifting Industry
- Minnesota Real Estate Agent Promotes New Target Marketing
- RE1 Advisor Expands Services to Texas